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CASE REPORT
Primary pulmonary adenocarcinoma in a 16-year-old
boy  a five-year follow-up
Ane Stillits Ma˚reng1, Seppo W. Langer2 and Uffe Bodtger1,3*
1Department of Respiratory Medicine, Naestved Hospital, Naestved, Denmark; 2Department of Oncology,
Head, Thoracic and Neuroendocrine Unit, Copenhagen University Hospital, Rigshospitalet, Copenhagen,
Denmark; 3Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark
Primary pulmonary adenocarcinoma in children or adolescents is a rare disease, and as such, there are no
randomised studies on lung cancer for this age group. Treatment choice is extrapolated from studies in adults
(mean age of participants: 60 years). We present the 5-year follow-up of a 16-year-old boy who presented with
metastatic primary pulmonary adenocarcinoma (T3N3M1a) and was treated aggressively, including radiation
therapy for local and distant recurrence. He had complete remission, had completed his education, was
employed full-time, and suffered only from mild side effects to treatment.
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A
16-year-old Caucasian boy was admitted to our
unit in January 2011 with a 2-month history of
shortness of breath during exercise, haemoptysis,
loss of appetite, and a weight loss of 3 kg. Labour, birth,
and childhood had been unremarkable. There was no his-
tory of no tobacco smoke exposure, previous childhood
cancer, environmental exposure to known cancerogenics,
or first- or second-generation relatives with cancer. He
attended ninth grade, was active with sports, and lived in
a rural town with his middle-class family. A chest x-ray
showed a mass in right lower lobe (RLL). At admission,
he presented with normal respiratory frequency, was slim
but not underweight, and a fixed bronchial obstruction at
auscultation in IC4 of the anterior left hemithorax.
A chest CT demonstrated two RLL lesions (T3), ipsi- and
contralateral mediastinal lymphadenopathy (N3),
and an intraluminal lesion obstructing left main bronchus
(M1a) (Fig. 1). Bronchoscopy and endobronchial ultra-
sound confirmed Tumor-Node-Metastasis (TNM) stage:
primary pulmonary adenocarcinoma with no signs of a
foetal subtype (positive immunohistochemical staining to
cytokeratine-7, TTF-1, and napsin with solitary cells
additionally positive to cytokeratin-5, P63, and vimentin;
all negative to placental alkaline phosphatase and synapto-
physin). The patient underwent immediate bronchoscopic
laser resection of tumour in the left main bronchus with
immediate relief of dysponea. Extensive histopathologically
workup showed no mutations of EGFR, KRAS, or BRAF,
no expression of ALK protein, no ALK-EML4 rearrange-
ment, and no ROS1 translocation. Stage was confirmed by
positron emission tomography (PET)-CT.
Downstaging was obtained with chemotherapy (nine
courses of cisplatin, vinorelbine plus bevacizumab), tho-
racic radiation therapy (66 Gy on 33 fractions, 5 fractions/
week), and additional three courses of platinum doublet.
Fig. 1. Contrast-enhanced chest CT at diagnosis. Arrows
show tumour mass in left main bronchus (upper image) and
in right lower lobe (lower image).
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An FDG PET-CT scan showed complete regression of
the left tumour. In April 2012, RLL was resected. Tumour
islets identical with primary cancer were found in stations
7 and 12R. Postoperatively, he received adjuvant platinum-
based chemotherapy.
Next-generation sequencing (Formalin-Fixed, Paraffin-
Embedded tissue (FFPE)-purified genomic DNA; Ion
AmpliSeq Cancer Hotspot Panel version 2) of the resected
tumour revealed a non-targetable mutation in KIT gene
(c.1676TA, p.V559D). The other 49 genes were without
mutations: ABL1, EZH2, JAK3, PTEN, AKT1, FBXW7,
IDH2, PTPN11, ALK, FGFR1, KDR, RB1, APC,
FGFR2, RET, ATM, FGFR3, KRAS, SMAD4, BRAF,
FLT3, MET, SMARCB1, CDH1, GNA11, MLH1, SMO,
CDKN2A, GNAS, MPL, SRC, CSF1R, GNAQ,
NOTCH1, STK11, CTNNB1, HNF1A, NPM1, TP53,
EGFR, HRAS, NRAS, VHL, ERBB2, IDH1, PDGFRA,
ERBB4, JAK2, and PIK3CA.
An FDG PET-CT scan was performed every 3 months.
In October 2014, an FDG-positive mediastinal lesion was
assessed by mediastinoscopy: no malignancy.
In April 2015, he underwent surgery for a solitary,
symptomatic cerebral metastasis, followed by stereotactic
radiation therapy (18 Gy1). In June 15, a biopsy-
confirmed mediastinal and cervical lymph node recurrence
was treated with nine series of docetaxel: partial remission
after three courses and complete remission after nine
courses. He continued clinical and PET-CT assessments
every 3 months.
At 5-year follow-up (January 2016), he was without
evidence of new recurrence. He had finished his com-
mercial education and started an employment at a
worldwide pharma industry. He had mild peripheral
lower limb neuropathy as only side effect to treatment.
Discussion
The incidence of primary lung cancer in persons under
18 years is less than 0.05/100,000 persons, and primary
pulmonary adenocarcinoma constitutesB10% of all cases
(14). Benign or secondary malignant lesions in the lung
are much more prevalent, though still rare. No specific
oncogenic drivers, mutations, genes, tumour antigens, or
other characteristics have been found in children or
adolescents with primary pulmonary adenocarcinoma,
though most patients have metastatic disease at presenta-
tion, and the 5-year survival is 25% (1, 2, 4). No ran-
domised clinical trials on childhood primary lung cancer
have been performed: almost an orphan disease, treatment
strategies are extrapolated from studies conducted in older
populations. In published reports on phase III-studies on
first- or second-line therapy of unresectable lung adeno-
carcinoma, median age was 60 years, and less than 1% was
below 30 years (519). Future studies on paediatric lung
cancer will probably focus on genetic promoter mutations,
as survival is improved when EGFR or KRAS mutations
are present (20). Our patient had no targetable mutations.
An increasingly aggressive approach to advanced or
metastatic non-small cell lung cancer (NSCLC) has
emerged during the last years: intended curative chemora-
diotherapy in locally advanced stages (21, 22), and inten-
ded curative surgery in M1b oligometastatic NSCLC with
single brain metastasis and a small primary lesion (23).
Our patient was offered extensive chemotherapy modified
from guidelines for adult patients with stage IV primary
pulmonary adenocarcinoma (24), and was successfully
downstaged as assessed by both Response Evaluation
Criteria In Solid Tumors (RECIST) criteria and invasive
tissue sampling. Using an aggressive approach including
surgical resection of single metastases, our patient had no
signs of new relapse at the control visit 5 years after
diagnosis and had only a minimum of persisting side
effects.
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